FDA refuses to file Novo Nordisk application
The FDA has refused to start filing Novo Nordisk's application for an expanded marketing authorization for Ozempic in a higher dose.
BY RITZAU FINANS & MEDWATCH, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk has received a Refusal to File letter from the US Food and Drug Administration (FDA) for its application for a version of Ozempic, which Novo Nordisk announces on Monday evening.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
